A compassionate use study of XPro™
Latest Information Update: 07 May 2024
At a glance
- Drugs Pegipanermin (Primary)
- Indications Alzheimer's disease
- Focus Expanded access; Therapeutic Use
- Sponsors INmune Bio
Most Recent Events
- 07 May 2024 New trial record
- 30 Apr 2024 According to an INmune Bio media release, company share an update on two patients from the Phase 1b trial completed in 2021 who have continued to receive XPro™ for treatment of Alzheimers Disease (AD) for more than three years under the Australian compassionate use program known as the Special Access Scheme (SAS).